AHCL
Anlon Healthcare financials
- Market cap
- ₹756 Cr
- Sector
- Healthcare
- Calls analysed
- 4
Anlon Healthcare Limited Q1 FY27
What went well
- Total income for Q1 FY27 grew by 163.03% YoY to ₹87.62 crores.
- EBITDA increased by 150% YoY to ₹15.65 crores.
- Profit after tax rose by 133.24% YoY to ₹8.28 crores.
What to watch
- EBITDA margin moderated to approximately 17% in Q1 FY27.
- Raw material prices increased 'two to three times' and are 'still not normalized' due to geopolitical situation.
What Anlon Healthcare Limited does
Anlon Healthcare Limited, incorporated in 2013 and based in Rajkot, Gujarat, is a research-driven chemical manufacturer of high-purity advanced pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs). Its intermediates and APIs serve as key starting materials and raw materials for finished dosage formulations (tablets, capsules, syrups, ointments), and it is among the few Indian manufacturers of Loxoprofen Sodium Dihydrate, Ketoprofen and Dexketoprofen Trometamol, key APIs used for pain and inflammation. The company also offers end-to-end custom manufacturing (CDMO) services, taking molecules from process development through commercial-scale production for global innovator clients, and separately makes nutraceutical products supplied to pharmaceutical, nutraceutical, personal care and animal-health customers.
Segments
- Active Pharmaceutical Ingredients (APIs)
- Pharmaceutical Intermediates
- Nutraceuticals
- Custom Manufacturing (CDMO)
- Installed manufacturing capacity
- 1,400-1,600 MTPA
- Manufacturing blocks
- 2 dedicated blocks (APIs & Intermediates) at Rajkot
- Capacity utilization
- 62.37%
- Product portfolio
- 65 commercialized, 28 in pilot stage, 49 under lab testing
- Drug Master Files (DMFs) filed
- 21
- Global presence
- 15 countries
Guidance record · Q1 FY27
what the last two calls moved 20 tracked 0 delivered 5 missed 15 open- Net Debt missed said Q2 FY26 Promised: by third quarter of next financial year, we will be the debt-free. No bank loan for new expansion. Q1 FY27: Confirmed taking on INR 70 CR of new debt for capex, cementing the reversal of the debt-free promise.
- FY27 Revenue revised down said Q2 FY26 Promised: minimum 360 to 400 CR after inorganic acquisition Q1 FY27: Revised FY27 guidance down to INR 350-400 CR, lowering the bottom end from the previous INR 380 CR.
- Revenue Growth on track said Q2 FY26 Promised: 30% plus revenue CAGR over the next three years Q1 FY27: Reiterated confidence in achieving approximately 30% revenue CAGR over the next three years.
All 20 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 162.9%, net profit up 133.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24 | 9 | 49 | 33 | 52 +116% | 36 +280% | 51 +4% | 88 +163% |
| EBITDA | 8 | 1 | 17 | 6 | 14 +83% | 12 +2017% | 15 −11% | 16 +150% |
| Net profit | 3 | -2 | 17 | 4 | 9 +260% | 5 +307% | 11 −34% | 8 +133% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −81.6% 1Y
1Y: ₹106.64 on 10 Sept 2025 → ₹19.57. High ₹168.61 (28 Nov 2025), low ₹13.11 (4 May 2026).
How the price took the results
close before → close after
- Q1 FY27
- −1.9%
- 6 Aug
- Q4 FY26
- +0.7%
- 3 Jun
- Q3 FY26
- −3.1%
- 19 Feb
- Q2 FY26
- +0.9%
- 19 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 43.0% a year over 1 year, FY25 to FY26. Operating margin widened to 27.7%.
| Year ending | FY25 | FY26 |
|---|---|---|
| Revenue | ₹120 Cr | ₹172 Cr |
| Operating profit | ₹32 Cr | ₹48 Cr |
| Operating margin | 26.7% | 27.7% |
| Interest | ₹4 Cr | ₹4 Cr |
| Depreciation | ₹2 Cr | ₹2 Cr |
| Net profit | ₹21 Cr | ₹29 Cr |
| Net margin | 17.7% | 16.9% |
| Cash from operations | ₹-23 Cr | ₹-79 Cr |
| Free cash flow | ₹-20 Cr | ₹-116 Cr |
| ROCE | — | 21.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹16 Cr | ₹53 Cr | ₹53 Cr |
| Reserves | ₹-10 Cr | ₹-10 Cr | ₹-5 Cr | ₹5 Cr | ₹161 Cr | ₹177 Cr |
| Borrowings | ₹54 Cr | ₹62 Cr | ₹70 Cr | ₹81 Cr | ₹58 Cr | ₹44 Cr |
| Other liabilities | ₹16 Cr | ₹21 Cr | ₹34 Cr | ₹26 Cr | ₹37 Cr | ₹100 Cr |
| Total liabilities | ₹71 Cr | ₹85 Cr | ₹112 Cr | ₹128 Cr | ₹309 Cr | ₹374 Cr |
| Fixed assets | ₹29 Cr | ₹27 Cr | ₹26 Cr | ₹27 Cr | ₹22 Cr | ₹58 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹2 Cr | ₹4 Cr | ₹1 Cr | ₹18 Cr | ₹1 Cr |
| Other assets | ₹43 Cr | ₹56 Cr | ₹82 Cr | ₹100 Cr | ₹269 Cr | ₹315 Cr |
| Total assets | ₹71 Cr | ₹85 Cr | ₹112 Cr | ₹128 Cr | ₹309 Cr | ₹374 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Sep 2025, FIIs added +1.67 pp while DIIs trimmed −1.60 pp. The shareholder count grew 178% to 34,671.
- Promoters
- 52.7%
- FIIs
- 1.7%
- DIIs
- 1.2%
- Public
- 44.4%
Since Sep 2025
- FIIs +1.67 pp
- DIIs −1.60 pp
- Public −0.06 pp
How it drifted, 4 quarters
Over this window FIIs went from 0.0% to 1.7% — +1.7 pp.
Ownership split by quarter, oldest first. Sep '25: Promoters 52.7%, DIIs 2.8%, Public 44.5%.Dec '25: Promoters 52.7%, FIIs 0.2%, DIIs 4.5%, Public 42.6%.Mar '26: Promoters 52.7%, FIIs 0.3%, DIIs 4.6%, Public 42.4%.Jun '26: Promoters 52.7%, FIIs 1.7%, DIIs 1.2%, Public 44.4%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Anlon Healthcare Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Punitkumar R Rasadia | 34.98% | unchanged |
| Meet Atulkumar Vachhani | 17.70% | unchanged |
| Shree Dwarikadhish Ventures Llp | 7.53% | unchanged |
| Ban Labs Private Limited | 5.27% | unchanged |
| Jay Mauleshkumar Ukani | 1.13% | unchanged |
| Harshad Rasiklal Sheth | 1.13% | unchanged |
| Luv Natwarlal Ukani | 1.13% | unchanged |
| Ramotiya Ramaben | 0.00% | unchanged |
| Rameshbhai Maganbhai Ramotiya | 0.00% | unchanged |
| Rasadia Khush Punitkumar | 0.00% | unchanged |
| Mamata Punitkumar Rasadia | 0.00% | unchanged |
| Vari Meetbhai Vachhani | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
All earnings calls (4)
Read the Q1 FY27 call →Learn to analyse Anlon Healthcare Limited
Guides on how to read this kind of business and the numbers that matter.